A Phase II Study of EL625 [Cenersen] in Patients in Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Trial Profile

A Phase II Study of EL625 [Cenersen] in Patients in Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2012

At a glance

  • Drugs Cenersen (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Actual patient number (20) added as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top